{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:43:04Z","timestamp":1791819784515,"version":"4.3.4"},"reference-count":274,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","award":["418\/10"],"award-info":[{"award-number":["418\/10"]}],"id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","award":["603\/16"],"award-info":[{"award-number":["603\/16"]}],"id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Israel National Nanotechnology Initiative"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.addr.2017.05.006","type":"journal-article","created":{"date-parts":[[2017,5,12]],"date-time":"2017-05-12T05:32:50Z","timestamp":1494567170000},"page":"120-142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":123,"special_numbering":"C","title":["Peptide ligand-modified nanomedicines for targeting cells at the tumor microenvironment"],"prefix":"10.1016","volume":"119","author":[{"given":"Ayelet","family":"David","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2017.05.006_bb0005","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc903","article-title":"Ligand-targeted therapeutics in anticancer therapy","volume":"2","author":"Allen","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.addr.2017.05.006_bb0010","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nrd3229","article-title":"Development trends for human monoclonal antibody therapeutics","volume":"9","author":"Nelson","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2017.05.006_bb0015","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1146\/annurev.immunol.18.1.813","article-title":"An address system in the vasculature of normal tissues and tumors","volume":"18","author":"Ruoslahti","year":"2000","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.addr.2017.05.006_bb0020","first-page":"2869","article-title":"NG2 proteoglycan-binding peptides target tumor neovasculature","volume":"59","author":"Burg","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2017.05.006_bb0025","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.tips.2012.02.002","article-title":"Peptides for cell-selective drug delivery","volume":"33","author":"Svensen","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.addr.2017.05.006_bb0030","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.addr.2017.05.006_bb0035","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrc1098","article-title":"The pathogenesis of cancer metastasis: the \u2018seed and soil\u2019 hypothesis revisited","volume":"3","author":"Fidler","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.addr.2017.05.006_bb0040","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ctrv.2008.11.005","article-title":"Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR","volume":"35","author":"Heinemann","year":"2009","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.addr.2017.05.006_bb0045","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/ijc.28950","article-title":"Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration","volume":"136","author":"Chen","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.addr.2017.05.006_bb0050","first-page":"1936","article-title":"Clinical significance of HER-2\/neu oncogene amplification in primary breast cancer","volume":"11","author":"Seshadri","year":"1993","journal-title":"The South Australian Breast Cancer Study Group. J Clin Oncol"},{"key":"10.1016\/j.addr.2017.05.006_bb0055","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2009.26.2071","article-title":"Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3weeks to patients with HER2-positive metastatic breast cancer","volume":"28","author":"Krop","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2017.05.006_bb0060","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.cbpa.2009.03.022","article-title":"Folate-targeted therapeutic and imaging agents for cancer","volume":"13","author":"Low","year":"2009","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.addr.2017.05.006_bb0065","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.1200\/JCO.2013.49.7685","article-title":"PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer","volume":"31","author":"Naumann","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.addr.2017.05.006_bb0070","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1023\/A:1010960900254","article-title":"Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo","volume":"18","author":"Ishida","year":"2001","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2017.05.006_bb0075","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1124\/pr.54.4.561","article-title":"Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway","volume":"54","author":"Qian","year":"2002","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.addr.2017.05.006_bb0080","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1200\/JCO.2002.20.6.1668","article-title":"Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin","volume":"20","author":"Seymour","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2017.05.006_bb0085","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3389\/fonc.2013.00222","article-title":"Tumor targeting via integrin ligands","volume":"3","author":"Marelli","year":"2013","journal-title":"Front. Oncol."},{"key":"10.1016\/j.addr.2017.05.006_bb0090","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s00432-011-0984-2","article-title":"Prognostic value of intercellular adhesion molecule (ICAM)-1 expression in breast cancer","volume":"137","author":"Schroder","year":"2011","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.addr.2017.05.006_bb0095","first-page":"641","article-title":"Heterogeneity of mucin gene expression in normal and neoplastic tissues","volume":"53","author":"Ho","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2017.05.006_bb0100","first-page":"6393","article-title":"Somatostatin receptor-mediated tumor-targeting drug delivery using octreotide-PEG-deoxycholic acid conjugate-modified N-deoxycholic acid-O","volume":"33","author":"Huo","year":"2012","journal-title":"N-hydroxyethylation chitosan micelles. Biomaterials"},{"key":"10.1016\/j.addr.2017.05.006_bb0105","first-page":"1481","article-title":"Targeted chemotherapy for triple-negative breast cancers via LHRH receptor","volume":"25","author":"Fost","year":"2011","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.addr.2017.05.006_bb0110","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1124\/jpet.105.098855","article-title":"Novel polymeric prodrug with multivalent components for cancer therapy","volume":"317","author":"Khandare","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.addr.2017.05.006_bb0115","first-page":"235","article-title":"Galectin expression in cancer diagnosis and prognosis: a systematic review","volume":"1855","author":"Thijssen","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.addr.2017.05.006_bb0120","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/annonc\/mdn692","article-title":"Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma","volume":"20","author":"Esmaeli","year":"2009","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.addr.2017.05.006_bb0125","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/bmt.2011.193","article-title":"Successful treatment with tandem consolidation using 90yttrium-ibritumomab tiuxetan (zevalin) and high-dose therapy with autologous PBSCT in a patient with relapsed mantle cell lymphoma presenting as multiple lymphomatous polyposis","volume":"47","author":"Han","year":"2011","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.addr.2017.05.006_bb0130","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/ajh.21177","article-title":"De novo maintenance therapy with denileukin diftitox (Ontak) in a patient with peripheral T-cell lymphoma is associated with prolonged remission","volume":"83","author":"Wong","year":"2008","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.addr.2017.05.006_bb0135","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1517\/14712598.3.1.179","article-title":"DAB389IL2 (ONTAK) fusion protein therapy of chronic lymphocytic leukaemia","volume":"3","author":"Frankel","year":"2003","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.addr.2017.05.006_bb0140","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1038\/sj.leu.2402677","article-title":"Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using mylotarg (gemtuzumab ozogamicin)","volume":"16","author":"Larson","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.addr.2017.05.006_bb0145","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/00001813-200208000-00002","article-title":"Gemtuzumab ozogamicin (CMA-676, mylotarg) for the treatment of CD33+ acute myeloid leukemia","volume":"13","author":"Voutsadakis","year":"2002","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.addr.2017.05.006_bb0150","first-page":"279","article-title":"Mylotarg approved for patients with CD33+ acute myeloid leukemia","volume":"4","author":"Sorokin","year":"2000","journal-title":"Clin. J. Oncol. Nurs."},{"key":"10.1016\/j.addr.2017.05.006_bb0155","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1358\/dot.2013.49.11.2020937","article-title":"Trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer","volume":"49","author":"Haddley","year":"2013","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.addr.2017.05.006_bb0160","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s13554-013-0008-7","article-title":"Brentuximab vedotin in CD30+ lymphomas","volume":"3","author":"Perini","year":"2013","journal-title":"Biol. Ther."},{"key":"10.1016\/j.addr.2017.05.006_bb0165","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2017.05.006_bb0170","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2017.05.006_bb0175","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1073\/pnas.172398299","article-title":"VEGF-Trap: a VEGF blocker with potent antitumor effects","volume":"99","author":"Holash","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2017.05.006_bb0180","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1200\/JCO.2003.08.092","volume":"21","author":"Morgan","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.addr.2017.05.006_bb0185","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.bbapap.2003.11.010","article-title":"Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis","volume":"1697","author":"Manley","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.addr.2017.05.006_bb0190","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1517\/13543784.13.12.1631","article-title":"Atrasentan: targeting the endothelin axis in prostate cancer","volume":"13","author":"Jimeno","year":"2004","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.addr.2017.05.006_bb0195","first-page":"19","article-title":"Targeted therapy in non-small-cell lung cancer","volume":"16","author":"Herbst","year":"2002","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.addr.2017.05.006_bb0200","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.ejca.2010.02.027","article-title":"Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth","volume":"46","author":"Barkan","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.addr.2017.05.006_bb0205","first-page":"3056","article-title":"Targeted antiangiogenic therapy for cancer using vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3","volume":"6","author":"Gutheil","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2017.05.006_bb0210","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/sj.bjc.6601576","article-title":"Integrins: roles in cancer development and as treatment targets","volume":"90","author":"Jin","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.addr.2017.05.006_bb0215","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1158\/1078-0432.CCR-06-2436","article-title":"Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation","volume":"13","author":"Jain","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2017.05.006_bb0220","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1021\/cr900317f","article-title":"Phage display in molecular imaging and diagnosis of cancer","volume":"110","author":"Deutscher","year":"2010","journal-title":"Chem. Rev."},{"key":"10.1016\/j.addr.2017.05.006_bb0225","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.2174\/138161210790945913","article-title":"Development of peptides as potential drugs for cancer therapy","volume":"16","author":"Li","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.addr.2017.05.006_bb0230","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/nbt1320","article-title":"Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumor targeting","volume":"25","author":"Qiu","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2017.05.006_bb0235","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc1891","article-title":"Immunotoxin therapy of cancer","volume":"6","author":"Pastan","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.addr.2017.05.006_bb0240","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1158\/1078-0432.CCR-0642-03","article-title":"Vascular targeting agents as cancer therapeutics","volume":"10","author":"Thorpe","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2017.05.006_bb0245","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/107327480200900207","article-title":"Future of monoclonal antibodies in the treatment of hematologic malignancies","volume":"9","author":"Reff","year":"2002","journal-title":"Cancer Control"},{"key":"10.1016\/j.addr.2017.05.006_bb0250","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.2174\/1381612043383944","article-title":"Cancer-specific ligands identified from screening of peptide-display libraries","volume":"10","author":"Mori","year":"2004","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.addr.2017.05.006_bb0255","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1021\/cen-v089n022.p013","article-title":"Improving peptides","volume":"89","author":"Thayer","year":"2011","journal-title":"Chem. Eng. News"},{"key":"10.1016\/j.addr.2017.05.006_bb0260","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/psc.717","article-title":"Current strategies for the development of peptide-based anti-cancer therapeutics","volume":"11","author":"Borghouts","year":"2005","journal-title":"J. Pept. Sci."},{"key":"10.1016\/j.addr.2017.05.006_bb0265","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/380364a0","article-title":"Organ targeting in vivo using phage display peptide libraries","volume":"380","author":"Pasqualini","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.addr.2017.05.006_bb0270","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1002\/adma.201200454","article-title":"Peptides as targeting elements and tissue penetration devices for nanoparticles","volume":"24","author":"Ruoslahti","year":"2012","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2017.05.006_bb0275","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1021\/bi901135x","article-title":"Peptide-based probes for targeted molecular imaging","volume":"49","author":"Lee","year":"2010","journal-title":"Biochemistry"},{"key":"10.1016\/j.addr.2017.05.006_bb0280","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ccr.2009.10.013","article-title":"Tissue-penetrating delivery of compounds and nanoparticles into tumors","volume":"16","author":"Sugahara","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.addr.2017.05.006_bb0285","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1021\/mp700073y","article-title":"From combinatorial chemistry to cancer-targeting peptides","volume":"4","author":"Aina","year":"2007","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2017.05.006_bb0290","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0301-472X(02)01008-1","article-title":"Combinatorial peptide library methods for immunobiology research","volume":"31","author":"Liu","year":"2003","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.addr.2017.05.006_bb0295","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1021\/co200101w","article-title":"High-throughput screening of one-bead-one-compound libraries: identification of cyclic peptidyl inhibitors against calcineurin\/NFAT interaction","volume":"13","author":"Liu","year":"2011","journal-title":"ACS Comb. Sci."},{"key":"10.1016\/j.addr.2017.05.006_bb0300","doi-asserted-by":"crossref","first-page":"6378","DOI":"10.1073\/pnas.87.16.6378","article-title":"Peptides on phage: a vast library of peptides for identifying ligands","volume":"87","author":"Cwirla","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2017.05.006_bb0305","article-title":"Tumor-targeting peptides from combinatorial libraries","author":"Liu","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2017.05.006_bb0310","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3389\/fimmu.2013.00302","article-title":"The structural basis of antibody-antigen recognition","volume":"4","author":"Sela-Culang","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2017.05.006_bb0315","doi-asserted-by":"crossref","first-page":"30937","DOI":"10.1074\/jbc.272.49.30937","article-title":"Systematic exploration of the antigen binding activity of synthetic peptides isolated from the variable regions of immunoglobulins","volume":"272","author":"Laune","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2017.05.006_bb0320","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1002388","article-title":"Structural consensus among antibodies defines the antigen binding site","volume":"8","author":"Kunik","year":"2012","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.addr.2017.05.006_bb0325","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/354082a0","article-title":"A new type of synthetic peptide library for identifying ligand-binding activity","volume":"354","author":"Lam","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.addr.2017.05.006_bb0330","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1021\/ar0201299","article-title":"Applications of one-bead one-compound combinatorial libraries and chemical microarrays in signal transduction research","volume":"36","author":"Lam","year":"2003","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.addr.2017.05.006_bb0335","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF01718701","article-title":"High-volume cellular screening for anticancer agents with combinatorial chemical libraries: a new methodology","volume":"2","author":"Salmon","year":"1996","journal-title":"Mol. Divers."},{"key":"10.1016\/j.addr.2017.05.006_bb0340","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1021\/co4000584","article-title":"High-throughput screening of one-bead-one-compound peptide libraries using intact cells","volume":"15","author":"Cho","year":"2013","journal-title":"ACS Comb. Sci."},{"key":"10.1016\/j.addr.2017.05.006_bb0345","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2310\/7290.2005.05169","article-title":"Near-infrared optical imaging of ovarian cancer xenografts with novel alpha 3-integrin binding peptide \u201cOA02\u201d","volume":"4","author":"Aina","year":"2005","journal-title":"Mol. Imaging"},{"key":"10.1016\/j.addr.2017.05.006_bb0350","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1126\/science.4001944","article-title":"Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface","volume":"228","author":"Smith","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.addr.2017.05.006_bb0355","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nm0396-299","article-title":"Toward cell-targeting gene therapy vectors: selection of cell-binding peptides from random peptide-presenting phage libraries","volume":"2","author":"Barry","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2017.05.006_bb0360","first-page":"385","article-title":"Techniques to decipher molecular diversity by phage display","volume":"357","author":"Christianson","year":"2007","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.addr.2017.05.006_bb0365","first-page":"5381","article-title":"Significance of blood vessel leakiness in cancer","volume":"62","author":"McDonald","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2017.05.006_bb0370","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nm0202-121","article-title":"Steps toward mapping the human vasculature by phage display","volume":"8","author":"Arap","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2017.05.006_bb0375","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/309030a0","article-title":"Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule","volume":"309","author":"Pierschbacher","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.addr.2017.05.006_bb0380","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1126\/science.279.5349.377","article-title":"Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model","volume":"279","author":"Arap","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.addr.2017.05.006_bb0385","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nrc724","article-title":"Specialization of tumour vasculature","volume":"2","author":"Ruoslahti","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.addr.2017.05.006_bb0390","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1006\/scbi.2000.0334","article-title":"Targeting tumor vasculature with homing peptides from phage display","volume":"10","author":"Ruoslahti","year":"2000","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.addr.2017.05.006_bb0395","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1021\/bi002101f","article-title":"Solution structures and integrin binding activities of an RGD peptide with two isomers","volume":"40","author":"Assa-Munt","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.addr.2017.05.006_bb0400","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1182\/blood-2008-04-150862","article-title":"The neovasculature homing motif NGR: more than meets the eye","volume":"112","author":"Corti","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.05.006_bb0405","first-page":"867","article-title":"Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells","volume":"62","author":"Curnis","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2017.05.006_bb0410","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1073\/pnas.1120790109","article-title":"Cooperative effects of aminopeptidase N (CD13) expressed by nonmalignant and cancer cells within the tumor microenvironment","volume":"109","author":"Guzman-Rojas","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2017.05.006_bb0415","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.drup.2005.10.002","article-title":"RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature","volume":"8","author":"Temming","year":"2005","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.addr.2017.05.006_bb0420","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1021\/jm9509410","article-title":"De novo antimicrobial peptides with low mammalian cell toxicity","volume":"39","author":"Javadpour","year":"1996","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2017.05.006_bb0425","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/12469","article-title":"Anti-cancer activity of targeted pro-apoptotic peptides","volume":"5","author":"Ellerby","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2017.05.006_bb0430","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/81183","article-title":"Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13)","volume":"18","author":"Curnis","year":"2000","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2017.05.006_bb0435","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1172\/JCI0215223","article-title":"Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration","volume":"110","author":"Curnis","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2017.05.006_bb0440","doi-asserted-by":"crossref","first-page":"47891","DOI":"10.1074\/jbc.M207500200","article-title":"Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif","volume":"277","author":"Colombo","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2017.05.006_bb0445","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/med.20238","article-title":"Targeted drug delivery and penetration into solid tumors","volume":"32","author":"Corti","year":"2012","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.addr.2017.05.006_bb0450","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/bjc.2013.347","article-title":"NGR-TNF, a novel vascular-targeting agent, does not induce cytokine recruitment of proangiogenic bone marrow-derived cells","volume":"109","author":"Di Matteo","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.addr.2017.05.006_bb0455","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1158\/0008-5472.CAN-03-1753","article-title":"Coupling tumor necrosis factor-alpha with alphaV integrin ligands improves its antineoplastic activity","volume":"64","author":"Curnis","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2017.05.006_bb0460","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1158\/0008-5472.CAN-04-4282","article-title":"Targeted delivery of IFNgamma to tumor vessels uncouples antitumor from counterregulatory mechanisms","volume":"65","author":"Curnis","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2017.05.006_bb0465","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1158\/1541-7786.663.2.12","article-title":"Enhancement of the antiangiogenic activity of interleukin-12 by peptide targeted delivery of the cytokine to alphavbeta3 integrin","volume":"2","author":"Dickerson","year":"2004","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.addr.2017.05.006_bb0470","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1073\/pnas.062189599","article-title":"A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo","volume":"99","author":"Porkka","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2017.05.006_bb0475","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1083\/jcb.200304132","article-title":"Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels","volume":"163","author":"Christian","year":"2003","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.addr.2017.05.006_bb0480","doi-asserted-by":"crossref","first-page":"37492","DOI":"10.1074\/jbc.M201194200","article-title":"The anti-HIV cytokine midkine binds the cell surface-expressed nucleolin as a low affinity receptor","volume":"277","author":"Said","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2017.05.006_bb0485","doi-asserted-by":"crossref","first-page":"21129","DOI":"10.1074\/jbc.270.36.21129","article-title":"Peptides which bind to E-selectin and block neutrophil adhesion","volume":"270","author":"Martens","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2017.05.006_bb0490","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/1529-0131(199904)42:4<641::AID-ANR6>3.0.CO;2-T","article-title":"Specific targeting of activated endothelium in rat adjuvant arthritis with a 99mTc-radiolabeled E-selectin-binding peptide","volume":"42","author":"Zinn","year":"1999","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.addr.2017.05.006_bb0495","first-page":"450","article-title":"A peptide mimic of E-selectin ligand inhibits sialyl Lewis X-dependent lung colonization of tumor cells","volume":"60","author":"Fukuda","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2017.05.006_bb0500","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/ijc.20214","article-title":"Suppression of tumor growth and metastasis by a VEGFR-1 antagonizing peptide identified from a phage display library","volume":"111","author":"An","year":"2004","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.addr.2017.05.006_bb0505","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1620\/tjem.185.173","article-title":"Expression of vascular endothelial growth factor gene and its receptor (flt-1) gene in urinary bladder cancer","volume":"185","author":"Sato","year":"1998","journal-title":"Tohoku J. Exp. Med."},{"key":"10.1016\/j.addr.2017.05.006_bb0510","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/nm1101-1194","article-title":"Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth","volume":"7","author":"Lyden","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2017.05.006_bb0515","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ygyno.2006.09.031","article-title":"The prognostic value of vascular endothelial growth factors (VEGFs)-A and -B and their receptor, VEGFR-1, in invasive breast carcinoma","volume":"104","author":"Mylona","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.addr.2017.05.006_bb0520","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nrc2524","article-title":"FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?","volume":"8","author":"Fischer","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.addr.2017.05.006_bb0525","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/cncr.24789","article-title":"Vascular endothelial growth factor receptor-1 in human cancer: concise review and rationale for development of IMC-18F1 (Human antibody targeting vascular endothelial growth factor receptor-1)","volume":"116","author":"Schwartz","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.addr.2017.05.006_bb0530","doi-asserted-by":"crossref","first-page":"43137","DOI":"10.1074\/jbc.M203103200","article-title":"A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor","volume":"277","author":"Hetian","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2017.05.006_bb0535","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/emboj\/19.7.1525","article-title":"Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis","volume":"19","author":"Binetruy-Tournaire","year":"2000","journal-title":"EMBO J."},{"key":"10.1016\/j.addr.2017.05.006_bb0540","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1016\/j.lfs.2006.08.005","article-title":"Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1","volume":"79","author":"Starzec","year":"2006","journal-title":"Life Sci."},{"key":"10.1016\/j.addr.2017.05.006_bb0545","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jconrel.2005.11.017","article-title":"A peptide competing with VEGF165 binding on neuropilin-1 mediates targeting of a chlorin-type photosensitizer and potentiates its photodynamic activity in human endothelial cells","volume":"111","author":"Tirand","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2017.05.006_bb0550","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0092-8674(00)81402-6","article-title":"Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor","volume":"92","author":"Soker","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.addr.2017.05.006_bb0555","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/(SICI)1097-0215(20000320)89:2<167::AID-IJC11>3.0.CO;2-9","article-title":"VEGF overexpression in clinically localized prostate tumors and neuropilin-1 overexpression in metastatic forms","volume":"89","author":"Latil","year":"2000","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.addr.2017.05.006_bb0560","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1016\/S0002-9440(10)63772-8","article-title":"Neuropilin-1 in human colon cancer: expression, regulation, and role in induction of angiogenesis","volume":"164","author":"Parikh","year":"2004","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.addr.2017.05.006_bb0565","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/ijc.10611","article-title":"Neuropilin-1 is differentially expressed in myoepithelial cells and vascular smooth muscle cells in preneoplastic and neoplastic human breast: a possible marker for the progression of breast cancer","volume":"101","author":"Stephenson","year":"2002","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.addr.2017.05.006_bb0570","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/sj.bjc.6602308","article-title":"A peptide corresponding to the neuropilin-1-binding site on VEGF(165) induces apoptosis of neuropilin-1-expressing breast tumour cells","volume":"92","author":"Barr","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.addr.2017.05.006_bb0575","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jconrel.2010.09.015","article-title":"A novel peptide specifically targeting the vasculature of orthotopic colorectal cancer for imaging detection and drug delivery","volume":"148","author":"Li","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2017.05.006_bb0580","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jconrel.2016.08.033","article-title":"Characterization of TCP-1 probes for molecular imaging of colon cancer","volume":"239","author":"Liu","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2017.05.006_bb0585","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1535-6108(03)00271-X","article-title":"Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis","volume":"4","author":"Joyce","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.addr.2017.05.006_bb0590","article-title":"Tumor penetrating peptides for improved drug delivery","author":"Ruoslahti","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2017.05.006_bb0595","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1126\/science.1183057","article-title":"Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs","volume":"328","author":"Sugahara","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.addr.2017.05.006_bb0600","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nbt0697-542","article-title":"Alpha v integrins as receptors for tumor targeting by circulating ligands","volume":"15","author":"Pasqualini","year":"1997","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2017.05.006_bb0605","first-page":"722","article-title":"Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis","volume":"60","author":"Pasqualini","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2017.05.006_bb0610","doi-asserted-by":"crossref","first-page":"6460","DOI":"10.1016\/j.biomaterials.2009.08.013","article-title":"E-selectin binding peptide-polymer-drug conjugates and their selective cytotoxicity against vascular endothelial cells","volume":"30","author":"Shamay","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2017.05.006_bb0615","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1073\/pnas.0610298104","article-title":"Biomimetic amplification of nanoparticle homing to tumors","volume":"104","author":"Simberg","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2017.05.006_bb0620","doi-asserted-by":"crossref","first-page":"7210","DOI":"10.1158\/0008-5472.CAN-07-6752","article-title":"Mitochondrial\/cell-surface protein p32\/gC1qR as a molecular target in tumor cells and tumor stroma","volume":"68","author":"Fogal","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2017.05.006_bb0625","doi-asserted-by":"crossref","first-page":"9381","DOI":"10.1073\/pnas.0403317101","article-title":"Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells","volume":"101","author":"Laakkonen","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2017.05.006_bb0630","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nm720","article-title":"A tumor-homing peptide with a targeting specificity related to lymphatic vessels","volume":"8","author":"Laakkonen","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2017.05.006_bb0635","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1158\/0008-5472.CAN-05-3876","article-title":"Lymphatic zip codes in premalignant lesions and tumors","volume":"66","author":"Zhang","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2017.05.006_bb0640","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3892\/or.2013.2545","article-title":"The relevance of EGFR overexpression for the prediction of the malignant transformation of oral leukoplakia","volume":"30","author":"Ries","year":"2013","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.addr.2017.05.006_bb0645","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1096\/fj.05-4058com","article-title":"Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics","volume":"19","author":"Li","year":"2005","journal-title":"FASEB J."},{"key":"10.1016\/j.addr.2017.05.006_bb0650","doi-asserted-by":"crossref","first-page":"5118","DOI":"10.1073\/pnas.0915146107","article-title":"From combinatorial peptide selection to drug prototype (II): targeting the epidermal growth factor receptor pathway","volume":"107","author":"Cardo-Vila","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2017.05.006_bb0655","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/jb\/mvm109","article-title":"Identification of a novel peptide ligand of human vascular endothelia growth factor receptor 3 for targeted tumour diagnosis and therapy","volume":"142","author":"Qin","year":"2007","journal-title":"J. Biochem."},{"key":"10.1016\/j.addr.2017.05.006_bb0660","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.bbagen.2011.07.016","article-title":"The transferrin receptor and the targeted delivery of therapeutic agents against cancer","volume":"1820","author":"Daniels","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.addr.2017.05.006_bb0665","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1172\/JCI44798","article-title":"Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma","volume":"121","author":"Staquicini","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2017.05.006_bb0670","doi-asserted-by":"crossref","first-page":"96","DOI":"10.2174\/0929866511307010096","article-title":"Identification of a novel peptide ligand of human transfrrin receptor 1 for targeted tumor delivery drug","volume":"20","author":"Xin","year":"2012","journal-title":"Protein Pept Lett"},{"key":"10.1016\/j.addr.2017.05.006_bb0675","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0093-7754(01)90277-5","article-title":"Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers","volume":"28","author":"Yu","year":"2001","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.addr.2017.05.006_bb0680","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1096\/fj.02-0280fje","article-title":"Identification of novel carrier peptides for the specific delivery of therapeutics into cancer cells","volume":"17","author":"Shadidi","year":"2003","journal-title":"FASEB J."},{"key":"10.1016\/j.addr.2017.05.006_bb0685","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(95)92839-1","article-title":"Breast cancer imaging with radiolabelled peptide from complementarity-determining region of antitumour antibody","volume":"346","author":"Sivolapenko","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2017.05.006_bb0690","first-page":"67","article-title":"Structure-function correlation and biostability of antibody CDR-derived peptides as tumour imaging agents","volume":"2","author":"Hussain","year":"1996","journal-title":"Biomed Pept Proteins Nucleic Acids"},{"key":"10.1016\/j.addr.2017.05.006_bb0695","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1074\/jbc.R100036200","article-title":"Hyaluronan-binding proteins: tying up the giant","volume":"277","author":"Day","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2017.05.006_bb0700","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0065-230X(08)60101-3","article-title":"CD44: structure, function, and association with the malignant process","volume":"71","author":"Naor","year":"1997","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.addr.2017.05.006_bb0705","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/cncr.10206","article-title":"The prognostic value of immunohistochemically detected CD44v3 and CD44v6 expression in patients with surgically staged vulvar carcinoma: a multicenter study","volume":"94","author":"Hefler","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.addr.2017.05.006_bb0710","first-page":"887","article-title":"Expression of the CD44v2-10 isoform confers a metastatic phenotype: importance of the heparan sulfate attachment site CD44v3","volume":"63","author":"Barbour","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2017.05.006_bb0715","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s10529-015-1896-z","article-title":"A CD44 specific peptide developed by phage display for targeting gastric cancer","volume":"37","author":"Zhang","year":"2015","journal-title":"Biotechnol. Lett."},{"key":"10.1016\/j.addr.2017.05.006_bb0720","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1158\/0008-5472.CAN-04-0129","article-title":"Identification of an active site on the laminin alpha5 chain globular domain that binds to CD44 and inhibits malignancy","volume":"64","author":"Hibino","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2017.05.006_bb0725","first-page":"13","article-title":"Recent advances in the regulation of CD44 expression and its role in inflammation and autoimmune diseases","volume":"52","author":"Gee","year":"2004","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"10.1016\/j.addr.2017.05.006_bb0730","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1023\/A:1018540610858","article-title":"CD44 in inflammation and metastasis","volume":"14","author":"Lesley","year":"1997","journal-title":"Glycoconj. J."},{"key":"10.1016\/j.addr.2017.05.006_bb0735","doi-asserted-by":"crossref","first-page":"10494","DOI":"10.1158\/0008-5472.CAN-05-0314","article-title":"Laminin alpha5 chain metastasis- and angiogenesis-inhibiting peptide blocks fibroblast growth factor 2 activity by binding to the heparan sulfate chains of CD44","volume":"65","author":"Hibino","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2017.05.006_bb0740","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s10585-011-9422-8","article-title":"Laminin alpha5-derived peptides modulate the properties of metastatic breast tumour cells","volume":"28","author":"Kusuma","year":"2011","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.addr.2017.05.006_bb0745","article-title":"Effect of CD44 binding peptide conjugated to an engineered inert matrix on maintenance of breast cancer stem cells and tumorsphere formation","volume":"8","author":"Yang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2017.05.006_bb0750","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/glycob\/cwu086","article-title":"Galectin-3 in angiogenesis and metastasis","volume":"24","author":"Funasaka","year":"2014","journal-title":"Glycobiology"},{"key":"10.1016\/j.addr.2017.05.006_bb0755","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/carcin\/bgh329","article-title":"Peptides specific to the galectin-3 carbohydrate recognition domain inhibit metastasis-associated cancer cell adhesion","volume":"26","author":"Zou","year":"2005","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.addr.2017.05.006_bb0760","doi-asserted-by":"crossref","first-page":"9434","DOI":"10.1021\/bi060264j","article-title":"Targeting heat shock proteins on cancer cells: selection, characterization, and cell-penetrating properties of a peptidic GRP78 ligand","volume":"45","author":"Kim","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.addr.2017.05.006_bb0765","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.bmcl.2008.01.060","article-title":"A cell-penetrating peptidic GRP78 ligand for tumor cell-specific prodrug therapy","volume":"18","author":"Yoneda","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.addr.2017.05.006_bb0770","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1021\/mp060122j","article-title":"Mechanistic studies of a peptidic GRP78 ligand for cancer cell-specific drug delivery","volume":"4","author":"Liu","year":"2007","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2017.05.006_bb0775","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.biocel.2008.09.027","article-title":"Molecular evolution of the cadherin superfamily","volume":"41","author":"Hulpiau","year":"2009","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.addr.2017.05.006_bb0780","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nrc1276","article-title":"Cell adhesion and signalling by cadherins and Ig-CAMs in cancer","volume":"4","author":"Cavallaro","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.addr.2017.05.006_bb0785","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.peptides.2009.05.010","article-title":"Identification of a novel dual E- and N-cadherin antagonist","volume":"30","author":"Devemy","year":"2009","journal-title":"Peptides"},{"key":"10.1016\/j.addr.2017.05.006_bb0790","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1158\/1535-7163.MCT-11-0566","article-title":"Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors","volume":"11","author":"Kurzrock","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.addr.2017.05.006_bb0795","doi-asserted-by":"crossref","first-page":"7051","DOI":"10.3892\/mmr.2015.4248","article-title":"Screening a novel FGF3 antagonist peptide with anti-tumor effects on breast cancer from a phage display library","volume":"12","author":"Wang","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.addr.2017.05.006_bb0800","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1158\/1541-7786.MCR-06-0069","article-title":"Targeting bladder tumor cells in vivo and in the urine with a peptide identified by phage display","volume":"5","author":"Lee","year":"2007","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.addr.2017.05.006_bb0805","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s00109-010-0671-9","article-title":"A novel melanoma-targeting peptide screened by phage display exhibits antitumor activity","volume":"88","author":"Matsuo","year":"2010","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.addr.2017.05.006_bb0810","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.peptides.2009.12.020","article-title":"Isolation of peptide ligands that interact specifically with human glioma cells","volume":"31","author":"Ho","year":"2009","journal-title":"Peptides"},{"key":"10.1016\/j.addr.2017.05.006_bb0815","doi-asserted-by":"crossref","unstructured":"A.L. Matsuo, A.S. Tanaka, M.A. Juliano, E.G. Rodrigues, L.R. Travassos, A novel melanoma-targeting peptide screened by phage display exhibits antitumor activity. J Mol Med (Berl) 88 1255\u20131264.","DOI":"10.1007\/s00109-010-0671-9"},{"key":"10.1016\/j.addr.2017.05.006_bb0820","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/nm1692","article-title":"Detection of colonic dysplasia in vivo using a targeted heptapeptide and confocal microendoscopy","volume":"14","author":"Hsiung","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2017.05.006_bb0825","doi-asserted-by":"crossref","first-page":"15919","DOI":"10.1073\/pnas.1312197110","article-title":"Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival","volume":"110","author":"Cieslewicz","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2017.05.006_bb0830","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1161\/ATVBAHA.111.235358","article-title":"Design and validation of a specific scavenger receptor class AI binding peptide for targeting the inflammatory atherosclerotic plaque","volume":"32","author":"Segers","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.addr.2017.05.006_bb0835","doi-asserted-by":"crossref","first-page":"7425","DOI":"10.4049\/jimmunol.172.12.7425","article-title":"Peptides identified through phage display direct immunogenic antigen to dendritic cells","volume":"172","author":"Curiel","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2017.05.006_bb0840","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood-2006-04-014878","article-title":"Red-cell ICAM-4 is a ligand for the monocyte\/macrophage integrin CD11c\/CD18: characterization of the binding sites on ICAM-4","volume":"109","author":"Ihanus","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.05.006_bb0845","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa0905680","article-title":"Tumor-associated macrophages and survival in classic Hodgkin's lymphoma","volume":"362","author":"Steidl","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2017.05.006_bb0850","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.ccr.2011.02.006","article-title":"CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3","volume":"19","author":"Chen","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.addr.2017.05.006_bb0855","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2217\/1750743X.1.1.83","article-title":"Tumor-associated macrophages as targets for tumor immunotherapy","volume":"1","author":"Weigert","year":"2009","journal-title":"Immunotherapy"},{"key":"10.1016\/j.addr.2017.05.006_bb0860","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/imm.12023","article-title":"Anti-tumour strategies aiming to target tumour-associated macrophages","volume":"138","author":"Tang","year":"2013","journal-title":"Immunology"},{"key":"10.1016\/j.addr.2017.05.006_bb0865","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1038\/mt.2010.148","article-title":"Enhanced induction of HIV-specific cytotoxic T lymphocytes by dendritic cell-targeted delivery of SOCS-1 siRNA","volume":"18","author":"Subramanya","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.addr.2017.05.006_bb0870","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1128\/JVI.02105-08","article-title":"Targeted delivery of small interfering RNA to human dendritic cells to suppress dengue virus infection and associated proinflammatory cytokine production","volume":"84","author":"Subramanya","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.addr.2017.05.006_bb0875","doi-asserted-by":"crossref","first-page":"7221","DOI":"10.1016\/j.biomaterials.2012.06.049","article-title":"Microparticle surface modifications targeting dendritic cells for non-activating applications","volume":"33","author":"Lewis","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2017.05.006_bb0880","series-title":"CRS Book Series Advances in Delivery Science and Technology","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/978-1-4939-3634-2_10","article-title":"Polymer-based DNA delivery systems for cancer immunotherapy","author":"David","year":"2016"},{"key":"10.1016\/j.addr.2017.05.006_bb0885","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1021\/mp200394t","article-title":"Nanomedicine(s) under the microscope","volume":"8","author":"Duncan","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2017.05.006_bb0890","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJM197609302951406","article-title":"The carrier potential of liposomes in biology and medicine (second of two parts)","volume":"295","author":"Gregoriadis","year":"1976","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2017.05.006_bb0895","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/jps.2600791202","article-title":"Optimization and upscaling of doxorubicin-containing liposomes for clinical use","volume":"79","author":"Amselem","year":"1990","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2017.05.006_bb0900","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nrd1632","article-title":"Recent advances with liposomes as pharmaceutical carriers","volume":"4","author":"Torchilin","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2017.05.006_bb0905","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0014-5793(77)80717-5","article-title":"Nanocapsules: a new type of lysosomotropic carrier","volume":"84","author":"Couvreur","year":"1977","journal-title":"FEBS Lett."},{"key":"10.1016\/j.addr.2017.05.006_bb0910","first-page":"653","article-title":"Non-liposomal nanocapsules, methodology and application","volume":"48","author":"Speiser","year":"1979","journal-title":"Front. Biol."},{"key":"10.1016\/j.addr.2017.05.006_bb0915","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrd1775","article-title":"Design and development of polymers for gene delivery","volume":"4","author":"Pack","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2017.05.006_bb0920","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/polc.5070510111","article-title":"Structure and properties of pharmacologically active polymers","volume":"51","author":"Ringsdorf","year":"1975","journal-title":"J. Polym. Sci. Polym. Symp."},{"key":"10.1016\/j.addr.2017.05.006_bb0925","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/3-540-12796-8_10","article-title":"Soluble synthetic polymers as potential drug carriers","volume":"57","author":"Duncan","year":"1984","journal-title":"Adv. Polym. Sci."},{"key":"10.1016\/j.addr.2017.05.006_bb0930","first-page":"83","article-title":"Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates","volume":"5","author":"Vasey","year":"1999","journal-title":"Cancer Research Campaign Phase I\/II Committee. Clin Cancer Res"},{"key":"10.1016\/j.addr.2017.05.006_bb0935","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0168-3659(01)00330-3","article-title":"Water soluble polymers in tumor targeted delivery","volume":"74","author":"Kopecek","year":"2001","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2017.05.006_bb0940","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0169-409X(02)00021-2","article-title":"The origin of pegnology","volume":"54","author":"Davis","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2017.05.006_bb0945","first-page":"1175","article-title":"The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities","volume":"35","author":"Hurwitz","year":"1975","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2017.05.006_bb0950","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1073\/pnas.79.2.626","article-title":"A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies","volume":"79","author":"Trouet","year":"1982","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2017.05.006_bb0955","first-page":"1693","article-title":"Characterization and anticancer activity of the micelle-forming polymeric anticancer drug adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer","volume":"50","author":"Yokoyama","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2017.05.006_bb0960","first-page":"587","article-title":"Micelles of poly(oxyethylene)-poly(oxypropylene) block copolymer (pluronic) as a tool for low-molecular compound delivery into a cell: phosphorylation of intracellular proteins with micelle incorporated [gamma-32P]ATP","volume":"26","author":"Slepnev","year":"1992","journal-title":"Biochem. Int."},{"key":"10.1016\/j.addr.2017.05.006_bb0965","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/00001813-199909000-00010","article-title":"Dendrimer-platinate: a novel approach to cancer chemotherapy","volume":"10","author":"Malik","year":"1999","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.addr.2017.05.006_bb0970","first-page":"6387","article-title":"A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs","volume":"46","author":"Matsumura","year":"1986","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2017.05.006_bb0975","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0168-3659(99)00248-5","article-title":"Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review","volume":"65","author":"Maeda","year":"2000","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2017.05.006_bb0980","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nrd2614","article-title":"Nanoparticle therapeutics: an emerging treatment modality for cancer","volume":"7","author":"Davis","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2017.05.006_bb0985","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jconrel.2011.09.063","article-title":"Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress","volume":"161","author":"Lammers","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2017.05.006_bb0990","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nrclinonc.2010.139","article-title":"Delivering nanomedicine to solid tumors","volume":"7","author":"Jain","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.addr.2017.05.006_bb0995","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.addr.2013.11.009","article-title":"Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology","volume":"66","author":"Bertrand","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2017.05.006_bb1000","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/cas.12152","article-title":"The link between infection and cancer: tumor vasculature, free radicals, and drug delivery to tumors via the EPR effect","volume":"104","author":"Maeda","year":"2013","journal-title":"Cancer Sci."},{"key":"10.1016\/j.addr.2017.05.006_bb1005","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S1359-6446(03)02988-X","article-title":"Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress","volume":"9","author":"Marcucci","year":"2004","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.addr.2017.05.006_bb1010","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1002\/anie.201307628","article-title":"Antibody-drug conjugates: an emerging concept in cancer therapy","volume":"53","author":"Chari","year":"2014","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.addr.2017.05.006_bb1015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biocel.2013.10.006","article-title":"A cell-based single-stranded DNA aptamer specifically targets gastric cancer","volume":"46","author":"Zhang","year":"2013","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.addr.2017.05.006_bb1020","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ejca.2003.07.001","article-title":"Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer-doxorubicin conjugates to human colon cancer cells","volume":"40","author":"David","year":"2004","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.addr.2017.05.006_bb1025","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1021\/mp5005492","article-title":"Mannosylated polyion complexes for in vivo gene delivery into CD11c(+) dendritic cells","volume":"12","author":"Raviv","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2017.05.006_bb1030","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.2967\/jnumed.111.099390","article-title":"A folate receptor-alpha-specific ligand that targets cancer tissue and not sites of inflammation","volume":"53","author":"Vaitilingam","year":"2012","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.addr.2017.05.006_bb1035","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd4519","article-title":"Principles in the design of ligand-targeted cancer therapeutics and imaging agents","volume":"14","author":"Srinivasarao","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2017.05.006_bb1040","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.4155\/tde.12.99","article-title":"Multivalent ligand: design principle for targeted therapeutic delivery approach","volume":"3","author":"Chittasupho","year":"2012","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.addr.2017.05.006_bb1045","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s10439-005-5779-1","article-title":"Targeting drugs to combinations of receptors: a modeling analysis of potential specificity","volume":"33","author":"Caplan","year":"2005","journal-title":"Ann. Biomed. Eng."},{"key":"10.1016\/j.addr.2017.05.006_bb1050","doi-asserted-by":"crossref","unstructured":"R. van der Meel, L.J. Vehmeijer, R.J. Kok, G. Storm, E.V. van Gaal, Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status. Adv Drug Deliv Rev 65 1284\u20131298.","DOI":"10.1016\/j.addr.2013.08.012"},{"key":"10.1016\/j.addr.2017.05.006_bb1055","doi-asserted-by":"crossref","first-page":"11306","DOI":"10.1021\/ja1043177","article-title":"The complex role of multivalency in nanoparticles targeting the transferrin receptor for cancer therapies","volume":"132","author":"Wang","year":"2010","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2017.05.006_bb1060","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.nano.2012.05.015","article-title":"Effect of ligand density, receptor density, and nanoparticle size on cell targeting","volume":"9","author":"Elias","year":"2013","journal-title":"Nanomedicine"},{"key":"10.1016\/j.addr.2017.05.006_bb1065","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1021\/nn305663e","article-title":"A systematic analysis of peptide linker length and liposomal polyethylene glycol coating on cellular uptake of peptide-targeted liposomes","volume":"7","author":"Stefanick","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2017.05.006_bb1070","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1021\/nl404391r","article-title":"Passive versus active tumor targeting using RGD- and NGR-modified polymeric nanomedicines","volume":"14","author":"Kunjachan","year":"2014","journal-title":"Nano Lett."},{"key":"10.1016\/j.addr.2017.05.006_bb1075","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.1021\/nn102055s","article-title":"A reexamination of active and passive tumor targeting by using rod-shaped gold nanocrystals and covalently conjugated peptide ligands","volume":"4","author":"Huang","year":"2010","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2017.05.006_bb1080","first-page":"4221","article-title":"Vascular endothelial growth factor and vascular targeting of solid tumors","volume":"21","author":"Brekken","year":"2001","journal-title":"Anticancer Res."},{"key":"10.1016\/j.addr.2017.05.006_bb1085","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1471-4914(02)02429-2","article-title":"Probing the structural and molecular diversity of tumor vasculature","volume":"8","author":"Pasqualini","year":"2002","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.addr.2017.05.006_bb1090","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1021\/bm5003009","article-title":"Ligand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy","volume":"15","author":"Zhong","year":"2014","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.addr.2017.05.006_bb1095","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0168-3659(03)00240-2","article-title":"Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin","volume":"91","author":"Schiffelers","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2017.05.006_bb1100","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1021\/mp100402n","article-title":"Comparison of active and passive targeting of docetaxel for prostate cancer therapy by HPMA copolymer-RGDfK conjugates","volume":"8","author":"Ray","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2017.05.006_bb1105","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1016\/j.biomaterials.2011.01.073","article-title":"Integrin-assisted drug delivery of nano-scaled polymer therapeutics bearing paclitaxel","volume":"32","author":"Eldar-Boock","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2017.05.006_bb1110","doi-asserted-by":"crossref","first-page":"8583","DOI":"10.1021\/nn402662d","article-title":"Cyclic RGD-linked polymeric micelles for targeted delivery of platinum anticancer drugs to glioblastoma through the blood-brain tumor barrier","volume":"7","author":"Miura","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2017.05.006_bb1115","doi-asserted-by":"crossref","first-page":"5660","DOI":"10.1016\/j.biomaterials.2009.06.026","article-title":"Targeted intracellular codelivery of chemotherapeutics and nucleic acid with a well-defined dendrimer-based nanoglobular carrier","volume":"30","author":"Kaneshiro","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2017.05.006_bb1120","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.biomaterials.2009.10.027","article-title":"The use of RGDGWK-lipopeptide to selectively deliver genes to mouse tumor vasculature and its complexation with p53 to inhibit tumor growth","volume":"31","author":"Samanta","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2017.05.006_bb1125","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1097\/CAD.0b013e3282a213ce","article-title":"Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects","volume":"18","author":"Garde","year":"2007","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.addr.2017.05.006_bb1130","doi-asserted-by":"crossref","first-page":"7320","DOI":"10.1158\/1078-0432.CCR-08-0804","article-title":"Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin","volume":"14","author":"Pastorino","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2017.05.006_bb1135","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1021\/mp400404p","article-title":"Dual targeted polymeric nanoparticles based on tumor endothelium and tumor cells for enhanced antitumor drug delivery","volume":"11","author":"Gupta","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2017.05.006_bb1140","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jconrel.2009.05.030","article-title":"NGR-modified micelles enhance their interaction with CD13-overexpressing tumor and endothelial cells","volume":"139","author":"Wang","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2017.05.006_bb1145","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3109\/1061186X.2010.504267","article-title":"The antiangiogenic efficacy of NGR-modified PEG-DSPE micelles containing paclitaxel (NGR-M-PTX) for the treatment of glioma in rats","volume":"19","author":"Zhao","year":"2011","journal-title":"J. Drug Target."},{"key":"10.1016\/j.addr.2017.05.006_bb1150","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/pat.1829","article-title":"Pro-apoptotic peptide-polymer conjugates to induce mitochondrial-dependent cell death","volume":"22","author":"Adar","year":"2011","journal-title":"Polymer Adv Tech"},{"key":"10.1016\/j.addr.2017.05.006_bb1155","doi-asserted-by":"crossref","first-page":"9525","DOI":"10.1016\/j.biomaterials.2011.08.072","article-title":"The effect of hydrophilic chain length and iRGD on drug delivery from poly(epsilon-caprolactone)-poly(N-vinylpyrrolidone) nanoparticles","volume":"32","author":"Zhu","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2017.05.006_bb1160","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.nano.2008.07.007","article-title":"Targeting of albumin-embedded paclitaxel nanoparticles to tumors","volume":"5","author":"Karmali","year":"2009","journal-title":"Nanomedicine"},{"key":"10.1016\/j.addr.2017.05.006_bb1165","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2147\/IJN.S40498","article-title":"Tumor-targeted liposomal drug delivery mediated by a diseleno bond-stabilized cyclic peptide","volume":"8","author":"Li","year":"2013","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2017.05.006_bb1170","doi-asserted-by":"crossref","first-page":"5906","DOI":"10.1021\/jm900308r","article-title":"Multivalent display of quinic acid based ligands for targeting E-selectin expressing cells","volume":"52","author":"Shamay","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2017.05.006_bb1175","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jconrel.2015.08.029","article-title":"Inhibition of primary and metastatic tumors in mice by E-selectin-targeted polymer-drug conjugates","volume":"217","author":"Shamay","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2017.05.006_bb1180","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ijpharm.2011.03.044","article-title":"Effective tumor targeting and enhanced anti-tumor effect of liposomes engrafted with peptides specific for tumor lymphatics and vasculature","volume":"411","author":"Herringson","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2017.05.006_bb1185","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1021\/nl1002526","article-title":"Hydrazone ligation strategy to assemble multifunctional viral nanoparticles for cell imaging and tumor targeting","volume":"10","author":"Brunel","year":"2010","journal-title":"Nano Lett."},{"key":"10.1016\/j.addr.2017.05.006_bb1190","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jconrel.2016.03.024","article-title":"Assessing the therapeutic efficacy of VEGFR-1-targeted polymer drug conjugates in mouse tumor models","volume":"229","author":"Shamay","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2017.05.006_bb1195","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1039\/C5BM00161G","article-title":"A7RC peptide modified paclitaxel liposomes dually target breast cancer","volume":"3","author":"Cao","year":"2015","journal-title":"Biomater Sci"},{"key":"10.1016\/j.addr.2017.05.006_bb1200","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1080\/10611860600947607","article-title":"Lipopeptide-based liposomes for DNA delivery into cells expressing neuropilin-1","volume":"14","author":"Slimani","year":"2006","journal-title":"J. Drug Target."},{"key":"10.1016\/j.addr.2017.05.006_bb1205","doi-asserted-by":"crossref","first-page":"13232","DOI":"10.1021\/acsami.6b01300","article-title":"Stabilized heptapeptide A7R for enhanced multifunctional liposome-based tumor-targeted drug delivery","volume":"8","author":"Ying","year":"2016","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.addr.2017.05.006_bb1210","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1016\/j.biomaterials.2009.11.047","article-title":"Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature","volume":"31","author":"Yu","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2017.05.006_bb1215","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.1016\/j.biomaterials.2013.04.062","article-title":"Nanoparticle-mediated drug delivery to tumor neovasculature to combat P-gp expressing multidrug resistant cancer","volume":"34","author":"Bai","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2017.05.006_bb1220","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1158\/0008-5472.CAN-11-3883","article-title":"\u201cOA02\u201d peptide facilitates the precise targeting of paclitaxel-loaded micellar nanoparticles to ovarian cancer in vivo","volume":"72","author":"Xiao","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2017.05.006_bb1225","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3109\/1061186X.2011.632011","article-title":"Peptide-directed HPMA copolymer-doxorubicin conjugates as targeted therapeutics for colorectal cancer","volume":"19","author":"Kopansky","year":"2011","journal-title":"J. Drug Target."},{"key":"10.1016\/j.addr.2017.05.006_bb1230","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2147\/IJN.S53310","article-title":"GE11-modified liposomes for non-small cell lung cancer targeting: preparation, ex vitro and in vivo evaluation","volume":"9","author":"Cheng","year":"2014","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2017.05.006_bb1235","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/iub.1002","article-title":"PolyIC GE11 polyplex inhibits EGFR-overexpressing tumors","volume":"64","author":"Abourbeh","year":"2012","journal-title":"IUBMB Life"},{"key":"10.1016\/j.addr.2017.05.006_bb1240","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1021\/acs.molpharmaceut.5b00568","article-title":"G3-C12 peptide reverses galectin-3 from foe to friend for active targeting cancer treatment","volume":"12","author":"Sun","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2017.05.006_bb1245","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2017.01.021","article-title":"Inhibition of CD44v3 and CD44v6 function blocks tumor invasion and metastatic colonization","author":"Zaiden","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2017.05.006_bb1250","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1021\/acs.bioconjchem.6b00020","article-title":"Inhibition of gene expression and cancer cell migration by CD44v3\/6-targeted polyion complexes","volume":"27","author":"Golan","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2017.05.006_bb1255","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.biomaterials.2014.10.007","article-title":"Tumor microenvironment sensitive doxorubicin delivery and release to glioma using angiopep-2 decorated gold nanoparticles","volume":"37","author":"Ruan","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2017.05.006_bb1260","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1021\/bc500529d","article-title":"DC3-decorated polyplexes for targeted gene delivery into dendritic cells","volume":"26","author":"Golani-Armon","year":"2015","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2017.05.006_bb1265","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jconrel.2004.09.023","article-title":"Targeting tumor angiogenic vasculature using polymer-RGD conjugates","volume":"102","author":"Mitra","year":"2005","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2017.05.006_bb1270","first-page":"2427","article-title":"Multifunctional polymeric micelles as cancer-targeted","volume":"6","author":"Nasongkla","year":"2006","journal-title":"MRI-ultrasensitive drug delivery systems. Nano Lett"},{"key":"10.1016\/j.addr.2017.05.006_bb1275","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1021\/bc9005283","article-title":"Tumor-targeting peptide conjugated pH-responsive micelles as a potential drug carrier for cancer therapy","volume":"21","author":"Wu","year":"2010","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2017.05.006_bb1280","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1021\/mp100228v","article-title":"Nanotheranostics and image-guided drug delivery: current concepts and future directions","volume":"7","author":"Lammers","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2017.05.006_bb1285","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.addr.2010.08.004","article-title":"Imaging and drug delivery using theranostic nanoparticles","volume":"62","author":"Janib","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2017.05.006_bb1290","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.2967\/jnumed.108.051243","article-title":"PET\/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles","volume":"49","author":"Lee","year":"2008","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.addr.2017.05.006_bb1295","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1096\/fj.05-4145fje","article-title":"MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle","volume":"19","author":"Mulder","year":"2005","journal-title":"FASEB J."},{"key":"10.1016\/j.addr.2017.05.006_bb1300","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jconrel.2008.07.014","article-title":"Tumor-targeted HPMA copolymer-(RGDfK)-(CHX-A\u2033-DTPA) conjugates show increased kidney accumulation","volume":"132","author":"Borgman","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2017.05.006_bb1305","doi-asserted-by":"crossref","first-page":"7676","DOI":"10.1158\/0008-5472.CAN-08-0689","article-title":"Quantitative molecular magnetic resonance imaging of tumor angiogenesis using cNGR-labeled paramagnetic quantum dots","volume":"68","author":"Oostendorp","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2017.05.006_bb1310","doi-asserted-by":"crossref","first-page":"12617","DOI":"10.1073\/pnas.152463399","article-title":"Nanocrystal targeting in vivo","volume":"99","author":"Akerman","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2017.05.006_bb1315","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1593\/neo.05352","article-title":"Nanoparticles for the optical imaging of tumor E-selectin","volume":"7","author":"Funovics","year":"2005","journal-title":"Neoplasia"},{"key":"10.1016\/j.addr.2017.05.006_bb1320","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/RLI.0b013e31829d03ec","article-title":"Ultrasound molecular imaging of E-selectin in tumor vessels using poly n-butyl cyanoacrylate microbubbles covalently coupled to a short targeting peptide","volume":"48","author":"Fokong","year":"2013","journal-title":"Investig. Radiol."},{"key":"10.1016\/j.addr.2017.05.006_bb1325","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1158\/0008-5472.CAN-03-3230","article-title":"In vivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe","volume":"64","author":"Moore","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2017.05.006_bb1330","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jconrel.2014.06.058","article-title":"Intra-colonic administration of a polymer-bound NIRF probe for improved colorectal cancer detection during colonoscopy","volume":"192","author":"Kogan-Zviagin","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2017.05.006_bb1335","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.ejps.2012.09.003","article-title":"The relative roles of charge and a recognition peptide in luminal targeting of colorectal cancer by fluorescent polyacrylamide","volume":"47","author":"Bloch","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2017.05.006_bb1340","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2016-311393","article-title":"Tumour-specific delivery of siRNA-coupled superparamagnetic iron oxide nanoparticles, targeted against PLK1, stops progression of pancreatic cancer","author":"Mahajan","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.addr.2017.05.006_bb1345","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ijpharm.2014.11.066","article-title":"Multi-modal detection of colon malignancy by NIR-tagged recognition polymers and ultrasound contrast agents","volume":"478","author":"Bloch","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2017.05.006_bb1350","first-page":"3981","article-title":"Actively-targeted LTVSPWY peptide-modified magnetic nanoparticles for tumor imaging","volume":"7","author":"Jie","year":"2012","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2017.05.006_bb1355","first-page":"3118","article-title":"Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3","volume":"46","author":"Thor","year":"1986","journal-title":"Cancer Res"},{"key":"10.1016\/j.addr.2017.05.006_bb1360","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1089\/cbr.2006.307","article-title":"Evidence of specificity of radiolabeled phage display peptides for the TAG-72 antigen","volume":"22","author":"Rusckowski","year":"2007","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.addr.2017.05.006_bb1365","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.canlet.2008.07.009","article-title":"A new TAG-72 cancer marker peptide identified by phage display","volume":"272","author":"Chen","year":"2008","journal-title":"Cancer Lett."},{"key":"10.1016\/j.addr.2017.05.006_bb1370","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1038\/onc.2011.537","article-title":"Transtumoral targeting enabled by a novel neuropilin-binding peptide","volume":"31","author":"Roth","year":"2011","journal-title":"Oncogene"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X17300625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X17300625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T10:31:05Z","timestamp":1659004265000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X17300625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":274,"alternative-id":["S0169409X17300625"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2017.05.006","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peptide ligand-modified nanomedicines for targeting cells at the tumor microenvironment","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2017.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}